Related references
Note: Only part of the references are listed.2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Gerhard Hindricks et al.
EUROPEAN HEART JOURNAL (2021)
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease
John W. Stanifer et al.
CIRCULATION (2020)
Management of Coronary Disease in Patients with Advanced Kidney Disease
S. Bangalore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges
Ashley Chen et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Prescribing and Safety of Direct-Acting Oral Anticoagulants Compared to Warfarin in Patients with Atrial Fibrillation on Chronic Hemodialysis
Estella Davis et al.
PHARMACY (2020)
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight
So-Ryoung Lee et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
Craig T. January et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Anticoagulation in chronic kidney disease: from guidelines to clinical practice
Viviana Aursulesei et al.
CLINICAL CARDIOLOGY (2019)
Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide
Jon Mabley et al.
THROMBOSIS RESEARCH (2019)
Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States
Konstantinos C. Siontis et al.
CIRCULATION (2018)
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2018)
Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients
Taizen Nakase et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation
Ying Xian et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Vitamin K-Dependent Carboxylation of Matrix Gla Protein Influences the Risk of Calciphylaxis
Sagar U. Nigwekar et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries
Ambra Villari et al.
FRONTIERS IN PHARMACOLOGY (2017)
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease
Miho Kimachi et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis
Xiaoli Wang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2016)
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF
Kevin E. Chan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
K. Martin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran
Peter Ellinghaus et al.
THROMBOSIS RESEARCH (2016)
The inflammatory protein Pentraxin 3 in cardiovascular disease
Francesco Fornai et al.
IMMUNITY & AGEING (2016)
Prevention of vasculopathy by vitamin K supplementation: Can we turn fiction into fact?
Vincent M. Brandenburg et al.
ATHEROSCLEROSIS (2015)
Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis
Kevin E. Chan et al.
CIRCULATION (2015)
Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment
Yukihiro Koretsune et al.
CIRCULATION JOURNAL (2015)
Changes in Renal Function in Patients With Atrial Fibrillation An Analysis From the RE-LY Trial
Michael Boehm et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Fibroblast Growth Factor-23 and Incident Atrial Fibrillation The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS)
Jehu S. Mathew et al.
CIRCULATION (2014)
Net Clinical Benefit of Antithrombotic Therapy in Patients With Atrial Fibrillation and Chronic Kidney Disease A Nationwide Observational Cohort Study
Anders Nissen Bonde et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Haemostasis in chronic kidney disease
Jens Lutz et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
Apixaban exerts anti-inflammatory effects in mesangial cells by blocking thrombin/protease-activated receptor-1 system
Yuji Ishibashi et al.
THROMBOSIS RESEARCH (2014)
EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary
Hein Heidbuchel et al.
EUROPEAN HEART JOURNAL (2013)
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
John W. Eikelboom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Fibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-Living Individuals CHS (Cardiovascular Health Study)
Joachim H. Ix et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Anticoagulants in atrial fibrillation patients with chronic kidney disease
Robert G. Hart et al.
NATURE REVIEWS NEPHROLOGY (2012)
Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease
Jonas Bjerring Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Vitamin K-Antagonists Accelerate Atherosclerotic Calcification and Induce a Vulnerable Plaque Phenotype
Leon J. Schurgers et al.
PLOS ONE (2012)
Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor
Mark Y. Chan et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Severe Renal Impairment and Stroke Prevention in Atrial Fibrillation Implications for Thromboprophylaxis and Bleeding Risk
Ricarda Marinigh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate
Sergey V. Brodsky et al.
KIDNEY INTERNATIONAL (2011)
Direct inhibitors of thrombin and factor Xa attenuate clot-induced mitogenesis and inflammatory gene expression in human vascular smooth muscle cells
Anke C. Rosenkranz et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients
Arlene M. Gallagher et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients
Joseph B. Muhlestein
THROMBOSIS AND HAEMOSTASIS (2010)
Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: Comparison with direct inhibitors of factor VIIa, XIa and thrombin
Pancras C. Wong et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Effect of Long-Term Clopidogrel Treatment on Platelet Function and Inflammation in Patients Undergoing Coronary Arterial Stenting
Mark J. Antonino et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Predictors of new-onset decline in kidney function in a general middle-european population
Rudolf P. Obermayr et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study
K. Yamagata et al.
KIDNEY INTERNATIONAL (2007)
Novel conformation-specific antibodies against matrix γ-carboxyglutamic acid (Gla) protein -: Undercarboxylated matrix Gla protein as marker for vascular calcification
LJ Schurgers et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Contribution of atrial fibrillation to incidence and outcome of ischemic stroke - Results from a population-based study
C Marini et al.
STROKE (2005)
Atherosclerotic risk factors and renal function in the elderly: the role of hyperfibrinogenaemia and smoking. Results from the Italian Longitudinal Study on Ageing (ILSA)
B Baggio et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2005)
Predictors of new-onset kidney disease in a community-based population
CS Fox et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Atrial fibrillation is associated with severe acute ischemic stroke
DA Dulli et al.
NEUROEPIDEMIOLOGY (2003)
Tobacco, hypertension, and vascular disease: Risk factors for renal functional decline in an older population
AJ Bleyer et al.
KIDNEY INTERNATIONAL (2000)
Share Paper
